| Diabetes Mellitus
Apidra vs Toujeo
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Apidra vs Toujeo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsToujeo has a higher rate of injection site reactions vs Apidra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Toujeo but not Apidra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Apidra
Toujeo
At A Glance
SC injection
With meals
Rapid-acting insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Inject SC within 15 minutes before a meal or within 20 minutes after starting a meal into the abdomen, thigh, or upper arm; generally use with an intermediate or long-acting insulin.
Continuous Subcutaneous Infusion (Insulin Pump) Administer by CSII using an insulin pump per manufacturer instructions; change reservoir at least every 48 hours; do not dilute or mix with other insulins in the pump.
Intravenous Administration Administer only under medical supervision; dilute to 0.05-1 unit/mL in 0.9% sodium chloride injection using polyvinyl chloride infusion bags.
Diabetes Mellitus, Type 1 (insulin-naive) Approximately one-third to one-half of total daily insulin dose SC once daily; remainder given as short-acting insulin divided between daily meals.
Diabetes Mellitus, Type 2 (insulin-naive) 0.2 units/kg SC once daily.
Switching from once-daily long/intermediate-acting insulin Start at same unit dose as prior once-daily long-acting insulin SC once daily; monitor glucose closely during initial weeks.
Switching from twice-daily long/intermediate-acting insulin Start at 80% of total daily NPH or insulin detemir twice-daily dosage SC once daily; monitor glucose frequently.
Contraindications
- During episodes of hypoglycemia
- Known hypersensitivity to insulin glulisine or any of the excipients in APIDRA
- Active hypoglycemia episode
- Hypersensitivity to insulin glargine or any excipient in Toujeo
Adverse Reactions
Most common (>=5%) Nasopharyngitis, hypoglycemia, upper respiratory tract infection, influenza, peripheral edema, arthralgia, headache
Serious Severe hypoglycemia, anaphylaxis and generalized allergic reactions, hypokalemia, lipodystrophy, worsening of diabetic retinopathy, acute painful peripheral neuropathy
Postmarketing Medication errors with long-acting insulins, localized cutaneous amyloidosis, hyperglycemia and hypoglycemia associated with injection into amyloidosis sites
Most common (>=5%) nasopharyngitis, upper respiratory tract infection, hypoglycemia
Serious severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, hypokalemia
Postmarketing localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injections into or away from amyloidosis areas
Pharmacology
Rapid-acting human insulin analog; lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, with more rapid onset and shorter duration of activity than regular human insulin when given subcutaneously.
Long-acting insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Apidra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Toujeo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Apidra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Toujeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Apidra
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Toujeo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Apidra.
No savings programs available for Toujeo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ApidraView full Apidra profile
ToujeoView full Toujeo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.